Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): Updated results

被引：0
|
作者：
Srinivas, S.
Roigas, J.
Gillessen, S.
Harmenberg, U.
De Mulder, P. H.
Fountzilas, G.
Vogelzang, N.
Peschel, C.
Flodgren, P.
Escudier, B.
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Charite, Berlin, Germany
[3] Kantonsspital St Gallen, St Gallen, Switzerland
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
[6] Papageorgiou Hosp, Thessaloniki, Greece
[7] Nevada Canc Inst, Las Vegas, NV USA
[8] Klinikum Rechts Der Isar, Munich, Germany
[9] Lund Univ Hosp, Lund, Sweden
[10] Inst Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5040
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) - final results
    Escudier, B.
    Srinivas, S.
    Roigas, J.
    Gillessen, S.
    Harmenberg, U.
    De Mulder, P. H.
    Fountzilas, G.
    Vogelzang, N.
    Peschel, C.
    Flodgren, P.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 299 - 300
  • [2] Continuous daily administration of sunitinib malate (SU11248) - A phase II study in patients (PTS) with cytokine-refractory metastatic renal cell carcinoma (MRCC)
    Escudier, Bernard
    Roigas, Jan
    Gillessen, Silke
    Srinivas, Sandhya
    Pisa, Pavel
    Vogelzang, Nicholas
    Fountzilas, George
    Peschel, Christian
    Baum, Charles M.
    De Mulder, Pieter
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 144 - 144
  • [3] A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC).
    De Mulder, P. H.
    Roigas, J.
    Gillessen, S.
    Srinivas, S.
    Pisa, P.
    Vogelzang, N.
    Fountzilas, G.
    Peschel, C.
    Baum, C.
    Escudier, B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 223S - 223S
  • [4] Sunitinib continuous daily dosing in patients with cytokine-refractory metastatic renal cell carcinoma: Final results of a phase II study
    Roigas, J.
    Peschel, C.
    Escudier, B.
    [J]. ONKOLOGIE, 2008, 31 : 179 - 180
  • [5] Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
    Escudier, Bernard
    Roigas, Jan
    Gillessen, Silke
    Harmenberg, Ulrika
    Srinivas, Sandhya
    Mulder, Sasja F.
    Fountzilas, George
    Peschel, Christian
    Flodgren, Per
    Maneval, Edna Chow
    Chen, Isan
    Vogelzang, Nicholas J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4068 - 4075
  • [6] A PHASE II STUDY OF S-1 IN PATIENTS (PTS) WITH CYTOKINE-REFRACTORY METASTATIC RENAL CELL CANCER (MRCC)
    Naito, S.
    Akaza, H.
    Usami, M.
    Tsukamoto, T.
    Shinohara, N.
    Tomita, Y.
    Namiki, M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 190 - 190
  • [7] Sunitinib in patients with cytokine-refiractory metastatic renal cell carcinoma (mRCC)
    George, D. J.
    Michaelson, M. D.
    Rosenberg, J. E.
    Redman, B. G.
    Hudes, G. R.
    Bukowski, R. M.
    Kim, S. T.
    Chen, I.
    Wilding, G.
    Motzer, R. J.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 304 - 304
  • [8] Sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results from a phase I/II study
    Redman, B. G.
    Hudes, G. R.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Renal safety of sunitinib treatment: A prospective study for patients (pts) with metastatic renal cell carcinoma (mRCC)
    Billemont, B.
    Rixe, O.
    Meric, J. B.
    Alexandre, J.
    Goldwasser, F.
    Izzedine, H.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 36 - 36
  • [10] Skin toxicity of sunitinib: Prospective analysis in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Billemont, B.
    Barete, S.
    Meric, J. B.
    Moguelet, P.
    Frances, C.
    Chosidow, O.
    Goldwasser, F.
    Rixe, O.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345